Translate the page
Feel free to ask any questions, leave your comments, wishes and suggestions regarding the Google Translation at our Telegram Chat.
Like this video

Xeophin (PreICO)

Developing a suite of Class Leading Immunotherapeutics

Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.

2.4
1 0 expert ratings
Benchy 2.4
Experts
-
-
-
View rating distribution
64 days 19 hours left
2018-08-20 - 2019-02-22
Token
XERA
PreICO Price
1 XERA = 0.50 USD
Price
1 XERA = 1 USD
Bonus
Available
Platform
Accepting
BTC, ETH, Fiat
Minimum investment
1 USD
Country
Whitelist/KYC
KYC & Whitelist
Restricted areas
USA, Canada, Australia
More on ICO
Report

About Xeophin

Xeophin Pt y Ltd is a Melbourne, Australia based, Biotech Company with a focus on imunomodulating technologies, and is commit ted to the research, development and commercialisation of new and novel medical treatment s, in a number of high grow th therapeutic areas such as inflammation.

Our mission and vision are simple: “Take our core technologies and drive them through our six step process. The outcome being a transaction ready and IP protected technolog y por t folio. From this Xeophin will under take commercialisation activities to achieve a significant royalt y deal, delivering value to our XeR A-1 Token holders”.

In his position as Chief Executive Of ficer, Troy Neilson brings significant, relevant and recent Biotech experience along with extensive management skills. Travis Molloy as Executive Chairman brings 15 years experience in the development stage Biotech space and governance. Caroline Cook as Non-Executive Director brings to the organisation a wealth of project management, outsourcing and leadership experience.

Xeophin is currently a private and unlisted Australian company. Formal policies and best practice from Corporate Governance to Financial Management have been implemented from inception. Xeophin will reorganise and transition it self into the USA , this entit y is referred to NewCo at this stage. It is the NewCo entit y that will seek SEC compliance and undertake the formal ICO*.

Bookmark
ICO KYC Report
Not conducted yet
KYC procedure verifies selected/specific team members only. It does not guarantee ICO success nor is a call for investment.
Missing or incorrect data? Let us know.

ICOs that might interest you

SOMESING

SOMESING is a social music service that incorporates blockchain technology so that prod...

Starts in 53 days 19 hours

cryptoworkplace

The safest innovative devices and systems to protect personal data and the client’s f...

12 days 7 hours left

Viaz

The utility of VIAZ is to provide a decentralized funding platform, connecting its user...

Starts in 57 days 19 hours

BlockEstate

US real estate fund issuing private equity in the form of security tokens through our p...

26 days 19 hours left
ICO Market Report - November 2018ICO Market Report - November 2018

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn more Got it